Skip to main content

Peer Review reports

From: The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

Original Submission
2 Aug 2021 Submitted Original manuscript
1 Nov 2021 Reviewed Reviewer Report - Vita Leonardi
12 Dec 2021 Reviewed Reviewer Report
21 Dec 2021 Author responded Author comments - Xiwen Bi
7 Jan 2022 Author responded Author comments - Xiwen Bi
Resubmission - Version 2
21 Dec 2021 Submitted Manuscript version 2
22 Jan 2022 Author responded Author comments - Xiwen Bi
Resubmission - Version 3
22 Jan 2022 Submitted Manuscript version 3
4 Feb 2022 Author responded Author comments - Xiwen Bi
Resubmission - Version 4
4 Feb 2022 Submitted Manuscript version 4
21 Feb 2022 Author responded Author comments - Xiwen Bi
Resubmission - Version 5
21 Feb 2022 Submitted Manuscript version 5
9 Mar 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
10 Mar 2022 Editorially accepted
15 Mar 2022 Article published 10.1186/s12885-022-09399-2

You can find further information about peer review here.

Back to article page